Abstract Library

#2972 Characteristics and Management of Paragangliomas, 10 Years Experience

Introduction: Paraganglioma (PG) is a rare extra-adrenal neuroendocrine tumor, with common sites of presentation being abdomen, and head and neck region. The majority of PGs appear to be sporadic. However, almost half of cases are associated with an inherited syndrome. The highest malignancy rates are seen in paragangliomas (PGs) associated with SDHB mutations, which are usually abdominal and secretory.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Sardo E, Cameselle-Garcia S, Casteras A, Toledo R, Acosta D,

Keywords: Paraganglioma, SDHB mutations, Functioning Tumors,

#2243 Somatostatin Analogs (SSAs) as Effective Treatment of Resectable, non Metastatic, non Functioning Pancreatic Neuroendocrine Tumors (NF-pNETs) in Patients Unfit for Surgery. A Case Series.

Introduction: SSAs are used to treat symptomatic functioning pNETs and to prolong progression free survival in metastatic, G1/G2, somatostatin receptor-positive pNETs. Pancreatic surgery is burdened with important morbidity and mortality, especially in patients with increased anaesthesiological risk.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Nessi C, Paiella S, Miotto M, Viviani E, Zingaretti C,

Keywords: somatostatin analogs, resectable pnets,

#1834 Sporadic Panglandular Non-Functioning pNET: New Entities? A Case Series

Introduction: Sporadic panglandular pancreatic neuroendocrine tumors (PanNETs) have never been described yet.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Zingaretti C, Malpaga A, Ficial M, Capelli P, Impellizzeri H,

Keywords: panglandular, Pan NETs, sporadic,

#1810 FOXM1 Is Strongly Associated with Cell Proliferation and Is Not Influenced by Metabolic Syndrome in GEP-NETS

Introduction: Gastro-entero-pancreatic neuroendocrine tumors(GEP-NETs) and metabolic syndrome(MS) are both increasing exponentially. MS has been associated with several non NET cancers.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Pereira R

Authors: Pereira R, Pereira S, Morais T, Costa M, Sampaio P,

Keywords: GEP-NETs, metabolic syndrome, FOXM1, IGF1R, IL-6, Ki67 ,

#1786 Targeted Therapies (TT) (Sunitinib and Everolimus) for Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET). A Case Series

Introduction: Sunitinib (Sun) and Everolimus (Eve) are effective treatments for advanced GEP-NET. Lack of standard treatment sequencing and potential toxicities may preclude it´s use.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Pérez de la Puente C

Authors: Pérez de la Puente C, Mando P, Rizzo M, Rivero S, Pesce V,

Keywords: TNE, therapy target,